Fiera Capital Corp Trims Holdings in Acceleron Pharma Inc (NASDAQ:XLRN)

Fiera Capital Corp cut its stake in Acceleron Pharma Inc (NASDAQ:XLRN) by 3.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 26,842 shares of the biopharmaceutical company’s stock after selling 867 shares during the quarter. Fiera Capital Corp’s holdings in Acceleron Pharma were worth $2,413,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its position in shares of Acceleron Pharma by 2.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 288,539 shares of the biopharmaceutical company’s stock valued at $15,299,000 after purchasing an additional 6,887 shares in the last quarter. Aviva PLC purchased a new position in shares of Acceleron Pharma in the fourth quarter valued at $2,312,000. Swiss National Bank grew its position in shares of Acceleron Pharma by 2.0% in the fourth quarter. Swiss National Bank now owns 86,000 shares of the biopharmaceutical company’s stock valued at $4,560,000 after purchasing an additional 1,700 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Acceleron Pharma by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 639,834 shares of the biopharmaceutical company’s stock valued at $33,923,000 after purchasing an additional 24,423 shares in the last quarter. Finally, FMR LLC grew its position in shares of Acceleron Pharma by 33.9% in the fourth quarter. FMR LLC now owns 7,962,235 shares of the biopharmaceutical company’s stock valued at $422,159,000 after purchasing an additional 2,014,679 shares in the last quarter. Institutional investors own 86.17% of the company’s stock.

In other news, CFO Kevin F. Mclaughlin sold 36,774 shares of the business’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $85.51, for a total value of $3,144,544.74. Following the completion of the sale, the chief financial officer now owns 15,216 shares of the company’s stock, valued at approximately $1,301,120.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Adam M. Veness sold 6,000 shares of the business’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $85.58, for a total value of $513,480.00. Following the completion of the sale, the senior vice president now directly owns 27,161 shares of the company’s stock, valued at approximately $2,324,438.38. The disclosure for this sale can be found here. 2.50% of the stock is currently owned by corporate insiders.

XLRN opened at $98.59 on Friday. The stock has a 50-day moving average price of $94.80 and a 200-day moving average price of $72.77. Acceleron Pharma Inc has a 12-month low of $37.01 and a 12-month high of $108.50. The company has a current ratio of 15.15, a quick ratio of 15.15 and a debt-to-equity ratio of 0.04.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.09). Acceleron Pharma had a negative return on equity of 30.14% and a negative net margin of 182.31%. The firm had revenue of $4.30 million during the quarter, compared to analysts’ expectations of $5.26 million. During the same quarter in the previous year, the company posted ($0.74) earnings per share. Acceleron Pharma’s revenue for the quarter was up 53.6% compared to the same quarter last year. On average, research analysts anticipate that Acceleron Pharma Inc will post -3.16 earnings per share for the current fiscal year.

Several brokerages have recently weighed in on XLRN. ValuEngine upgraded Acceleron Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. JPMorgan Chase & Co. boosted their target price on Acceleron Pharma from $108.00 to $118.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Cowen boosted their target price on Acceleron Pharma from $78.00 to $109.00 in a research report on Tuesday, January 28th. Oppenheimer boosted their target price on Acceleron Pharma from $112.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. Finally, Goldman Sachs Group cut Acceleron Pharma from a “neutral” rating to a “sell” rating and set a $73.00 target price for the company. in a research report on Monday, April 6th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have issued a buy rating to the company. Acceleron Pharma presently has an average rating of “Buy” and an average price target of $111.85.

About Acceleron Pharma

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Featured Story: Why are trading ranges significant?

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.